Strontium still authorised despite an unfavourable opinion of the European Pharmacovigilance committee.
In 2014 the indications of strontium ranelate were further restricted in the European Union, and the French pharmacoeconomic committee has finally judged strontium ranelate to have "insufficient medical benefit".